Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 901–1,000 of 1,041
Zheng, W., Yin, T., Chen, Q., Qin, X., Huang, X., Zhao, S., Xu, T., Chen, L., & Liu, J. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.11.041 · Cited by 97
Jia, L., Li, Z., Shen, J., Zheng, D., Tian, X., Guo, H., & Chang, P. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.010 · Cited by 93
“…(ATP)-binding cassette (ABC) transporters and functions as an energy-dependent drug efflux pump that can actively pump out a variety of hydrophobic anticancer drugs from the target cancer cells and hence reduces the intracellular accumulation of drugs (Gottesman et al., 2002; Loo and Clarke, 2005).”
BackgroundNanoparticle therapeutics: Technologies and methods for overcoming cancer
Cerqueira, B. B. S., Lasham, A., Shelling, A. N., & Al‐Kassas, R. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.10.007 · Cited by 101
Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers
Lamberti, M., Zappavigna, S., Sannolo, N., Porto, S., & Caraglia, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.913568 · Cited by 96
Melanoma stem cells: not rare, but well done
Girouard, S. D., & Murphy, G. F. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.50 · Cited by 105
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.031 · Cited by 92
“One of the main players in MDR mechanisms is a drug efflux transport protein, Pgp that transports drugs out of tumor cells [16].”
BackgroundKhalili‐Tanha, G., Radisky, E. S., Radisky, D. C., & Shoari, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06447-w · Cited by 112
“Common chemotherapy agents like paclitaxel or doxorubicin can select for cells that overexpress ABC transporters (ABCB1, ABCC1, ABCC2), drastically diminishing intracellular drug accumulation [243–245].”
Oh, N. M., Oh, K. T., Baik, H. J., Lee, B. R., Lee, A. H., Youn, Y. S., & Lee, E. S. (2010) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2010.02.023 · Cited by 98
Zoghbi, S. S., Liow, J., Yasuno, F., Hong, J. S., Tuan, E. W., Lazarova, N., Gladding, R. L., Pike, V. W., & Innis, R. B. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047308 · Cited by 92
“For example, overexpression of P-gp is partly responsible for multidrug resistance in some cancers, because P-gp blocks the entry of selective chemotherapies into the cytoplasm of the tumor ( 1 ).”
BackgroundInfluentialCurry, D. E., Cameron, A., MacDonald, B., Nganou, C., Scheller, H., Marsh, J., Beale, S., Lü, M., Shan, Z., Kaliaperumal, R., et al. (2015) · Nanoscale · doi:10.1039/c5nr05826k · Cited by 93
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents
DeBono, A., Capuano, B., & Scammells, P. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501180v · Cited by 95
Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy
Li, Q., Chao, Y., Liu, B., Xiao, Z., Yang, Z., Wu, Y., & Liu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121880 · Cited by 92
Zhao, B., Sun, Y., Wang, S., Duan, L., Huo, Q.-L., Ren, F., & Li, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071071 · Cited by 91
“Recently, P-gp associated MDR is proved to be effectively overcome by either blocking its drug-pump function or inhibiting its expression [4].”
BackgroundGarcía, M. G., Alaniz, L. D., Lopes, E. C., Blanco, G. A. C., Hajos, S. E., & Álvarez, É. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.004 · Cited by 91
“The major mechanism in the development of MDR is the overexpression of transporter proteins such as phospho-glycoprotein (Pgp), which is encoded by a small family of closely related mdr genes (reviewed in [1]).”
BackgroundZhou, Y., Hu, Y., Yang, M., Jat, P., Li, K., Lombardo, Y., Xiong, D., Coombes, R. C., Raguz, S., & Yagüe, E. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.167 · Cited by 97
Yang, X., Iyer, A. K., Singh, A., Milane, L. S., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1602-1 · Cited by 91
Wong, I. L. K., Chan, K., Tsang, K. H., Lam, C. Y., Zhao, Y., Chan, T. H., & Chow, L. M. C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900194w · Cited by 102
Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology
Pang, L. Y., & Argyle, D. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.010 · Cited by 109
“Integrating Canine and Feline Models to Develop New Therapies With the evolution of the cancer stem cell theory, investigators have focused on potential therapeutic targets including signalling pathways and mechanisms that contribute to drug resistance (Table 3 and references [133-175]).”
BackgroundSauna, Z. E., Peng, X.-H., Nandigama, K., Tekle, S., & Ambudkar, S. V. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.675 · Cited by 100
“The overexpression of the energy-dependent efflux membrane proteins P-glycoprotein (Pgp or ABCB1), multidrug resistance protein 1 (MRP1 or ABCC1), and the mitoxantrone-resistance–associated protein (ABCG2) have been strongly associated with MDR (Gottesman et al., 2002).”
BackgroundInfluentialAmbudkar, S. V., Sauna, Z. E., Gottesman, M. M., & Szakács, G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.06.001 · Cited by 91
“Resistance to chemotherapy in metastatic cancers has been correlated with the overexpression of energy-dependent efflux pumps [7].”
BackgroundSelf-citationZhang, F. Y., Du, G. J., Zhang, L., Zhang, C. L., Lü, W.-L., & Liang, W. P. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9793-y · Cited by 96
Sui, H., Zhou, S., Wang, Y., Liu, X., Zhou, L., Yin, P., Fan, Z., & Li, Q. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr016 · Cited by 90
Multifunctional Nanosystem for Synergistic Tumor Therapy Delivered by Two-Dimensional MoS2
Peng, M., Zheng, D., Wang, S., Cheng, S., & Zhang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03276 · Cited by 91
A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance
Zhang, C., Liu, L., Qiu, W., Zhang, Y., Song, W., Zhang, L., Wang, S., & Zhang, X. (2018) · Small · doi:10.1002/smll.201703321 · Cited by 90
Xing, Y., Ding, T., Wang, Z., Wang, L., Guan, H., Tang, J., Mo, D., & Zhang, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b00472 · Cited by 90
Guo, W., Chen, Z., Feng, X., Shen, G., Huang, H., Liang, Y., Zhao, B., Li, G., & Hu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00874-9 · Cited by 93
“MDR is highly associated with transmembrane efflux pumps such as P-gp, which belongs to the adenosine triphosphate (ATP)-binding cassette (ABC) transporter superfamily [49, 50].”
RetractedDelivering metal ions by nanomaterials: Turning metal ions into drug-like cancer theranostic agents
Liu, C., Guo, L., Wang, Y., Zhang, J., & Fu, C. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215332 · Cited by 97
Shan, J., Xuan, Y., Ruan, S.-Q., & Sun, M. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0815-y · Cited by 90
Solute carriers (SLCs) in cancer
El-Gebali, S., Bentz, S., Hediger, M. A., & Anderle, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.007 · Cited by 96
Mukhopadhyay, R., Mukherjee, S., Mukherjee, B., Naskar, K., Mondal, D., Decuypere, S., Ostyn, B., Prajapati, V. K., Sundar, S., Dujardin, J., et al. (2011) · International Journal for Parasitology · doi:10.1016/j.ijpara.2011.07.013 · Cited by 90
“Over-expression of ABC transporters such as MDR1 (P-gp) or MRP1 on host cells causes multiple drug resistance in different diseases (Borst and Elferink, 2002) such as cancer (Gottesman et al., 2002; Luqmani, 2005), HIV infection or mycobacterium-HIV coinfection (Gollapudi et al.”
BackgroundInteraction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
Eadie, L. N., Hughes, T. P., & White, D. L. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.208 · Cited by 91
Velma, V., Dasari, S. R., & Tchounwou, P. B. (2016) · Biomarker Insights · doi:10.4137/bmi.s39445 · Cited by 98
Wei, J., Shuai, X., Wang, R., He, X., Li, Y., Ding, M., Li, J., Tan, H. S., & Fu, Q. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.005 · Cited by 91
Tombline, G., Bartholomew, L. A., Urbatsch, I. L., & Senior, A. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404689200 · Cited by 90
Hu, T., Wang, L., Zhang, L., Lu, L., Shen, J., Chan, R. L. Y., Li, M., Wu, W. K. K., To, K. K. W., & Cho, C. H. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.03.010 · Cited by 91
Willaime, J. M. Y., Turkheimer, F., Kenny, L. M., & Aboagye, E. O. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/2/187 · Cited by 89
Lineweaver, C. H., Davies, P. C. W., & Vincent, M. D. (2014) · BioEssays · doi:10.1002/bies.201400070 · Cited by 92
Bui, Q. N., Li, Y., Jang, M.-S., Huỳnh, Đ. P., Lee, J. H., & Lee, D. S. (2015) · Macromolecules · doi:10.1021/acs.macromol.5b00423 · Cited by 92
Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways
Muthusamy, G., Kanimozhi, G., Bharathiraja, P., Khan, H. A., Alhomida, A. S., Ekhzaimy, A. A., Brindha, G., & Prasad, N. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111632 · Cited by 93
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
Sun, G., Rong, D., Li, Z., Sun, G., Wu, F., Li, X., Cao, H., Cheng, Y., Tang, W., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694363 · Cited by 91
“Multidrug resistance protein 1 (MDR1) is a transporter with extensive substrate specificity and the ability to excrete many exogenous substances from the cell, including Vinblastine, podophyllotoxin, Anthracycline, Taxanes, and kinase inhibitors (Gottesman et al., 2002; Szakács et al., 2004).”
BackgroundOrganic nanoscale drug carriers coupled with ligands for targeted drug delivery in cancer
Shi, M., Lu, J., & Shoichet, M. S. (2009) · Journal of Materials Chemistry · doi:10.1039/b822319j · Cited by 103
Oloo, E. O., & Tieleman, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405084200 · Cited by 89
Lim, M. C., Song, Y. J., Seo, S., Yoo, C.-W., Kang, S., & Park, S. (2010) · Onkologie · doi:10.1159/000313823 · Cited by 92
Ikemura, K., Yamamoto, M., Miyazaki, S., Mizutani, H., Iwamoto, T., & Okuda, M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081844 · Cited by 93
“, 2003); it plays a key role in the pharmacokinetics of P-gp substrates and the multidrug resistance of cancer cells (Cordon-Cardo et al., 1990; Gottesman et al., 2002).”
BackgroundMaley, C. C., Reid, B. J., & Forrest, S. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1375.13.8 · Cited by 89
“Our estimates of the efficacy of cytotoxic therapies are probably overly optimistic because we did not simulate the phenomenon of single mutations that confer multidrug resistance (22).”
Solary, É., Drénou, B., Campos, L., de Crémoux, P., Mugneret, F., Moreau, P., Lioure, B., Falkenrodt, A., Witz, B., Bernard, M., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3419 · Cited by 96
“Red cell transfusion, units (range) 11 (3-50) 12 (2-38) NS”
BackgroundMethodInfluentialFu, P., Kong, F., Li, X., Wang, Y., & Zhu, W. (2014) · Organic Letters · doi:10.1021/ol501523d · Cited by 95
Pramanik, D., Campbell, N. R., Das, S., Gupta, S., Chenna, V., Bisht, S., Sysa‐Shah, P., Bedja, D., Karikari, C. A., Steenbergen, C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.543 · Cited by 96
“One key cause of acquired multidrug resistance is through energy-dependent efflux of cytotoxic agents through any of a 48-member family of ATP-binding cassette (ABC) transporters [2, 4, 5].”
Castillo, R. R., Baeza, A., & Vallet‐Regí, M. (2017) · Biomaterials Science · doi:10.1039/c6bm00872k · Cited by 89
Resistin: An inflammatory cytokine with multi-faceted roles in cancer
Sudan, S. K., Deshmukh, S. K., Poosarla, T., Holliday, N. P., Dyess, D. L., Singh, A. P., & Singh, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188419 · Cited by 95
Lebedeva, I. V., Pande, P., & Patton, W. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022429 · Cited by 88
“organisms from prokaryotes to mammals [2].”
Miraglia, E., Viarisio, D., Riganti, C., Costamagna, C., Ghigo, D., & Bosia, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20959 · Cited by 86
“' 2005 Wiley-Liss, Inc. Key words: multidrug resistance; Naþ/Hþ exchanger; colon carcinoma; doxorubicin Multidrug resistance (MDR) includes the numerous strategies by which tumor cells can elude the cytotoxic effect of chemotherapeutic agents and develop cross-resistance to a broad spectrum of drugs.1 Decreased accumu…”
BackgroundInfluentialSide Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance
Luo, Y., Ellis, L. Z., Dallaglio, K., Takeda, M. R., Robinson, W. A., Robinson, S. E., Liu, W., Lewis, K. D., McCarter, M. D., Gonzalez, R. C., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.161 · Cited by 91
“This phenotype of low fluorescent staining pattern results from a family of transporter proteins known as ATPbinding cassette (ABC) transporters, which are responsible for the exclusion of Hoechst 33342 (Helmbach et al., 2001; Gottesman et al., 2002).”
BackgroundInduction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells
Choi, H., Yang, J. W., Roh, S. H., Han, C. Y., & Kang, K. W. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0016 · Cited by 89
“One of the most important reasons for cancer chemotherapy resistance is the increased expression of the drug transporters that causes the efflux of the chemotherapeutic agents from the cancer cells (Gottesman et al. 2002).”
BackgroundPusztai, L., Jeong, J., Gong, Y. Y., Ross, J. S., Kim, C., Paik, S., Rouzier, R., André, F., Hortobágyi, G. N., Wolmark, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6887 · Cited by 88
Brancato, V., Gioiella, F., Imparato, G., Guarnieri, D., Urciuolo, F., & Netti, P. A. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.055 · Cited by 86
MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma
Manohar, C. F., Bray, J. A., Salwen, H. R., Madafiglio, J., Cheng, A. J., Flemming, C. L., Marshall, G. M., Norris, M. D., Haber, M., & Cohn, S. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207151 · Cited by 88
“…suggests that MRP1 is critically associated with the drug-resistant behavior of primary NB (Norris et al., 1996; Matsunaga et al., 1998; Bader et al., 1999), this drug efflux pump does not appear to mediate resistance to either alkylating agents or platinum compounds (Gottesman et al., 2002).”
BackgroundTargeting multidrug resistance in cancer by natural chemosensitizers
Hamed, A. R., Abdel‐Azim, N. S., Shams, K. A., & Hammouda, F. M. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0043-8 · Cited by 93
“…the pre-existing constitutive overexpression of cancer cell detoxification system before the start of chemotherapeutic regimen, or “acquired” where it develops after the start of the chemotherapy over time or after a secondary chemotherapy with tumor relapse (Gottesman 2002; Quintieri et al. 2007).”
BackgroundNanoparticles‐Mediated Combination Therapies for Cancer Treatment
Shrestha, B., Tang, L., & Romero, G. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900076 · Cited by 98
Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Lemmens‐Gruber, R., Kamyar, M.-R., & Dornetshuber, R. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787581761 · Cited by 98
Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance
McCubrey, J. A., Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W. H., Wong, E. W. T., Lehmann, B. D., Terrian, D. M., Bäsecke, J., Stivala, F., et al. (2007) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.12.013 · Cited by 97
“In some cases, this phenomenon has been shown to be due to the increased expression of membrane transporters (Gottesman et al., 2002; Norgaard et al., 2004; van den HeuvelEibrink et al., 2000; Ross 2000; Kruh et al., 2003).”
Lugo, M. R., & Sharom, F. J. (2005) · Biochemistry · doi:10.1021/bi0511179 · Cited by 87
Çakıl, Y. D., Akhmetova, L., İşeri, Ö. D., Kars, M. D., & Gündüz, U. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1385-y · Cited by 92
“In particular, an estimated 40% of all breast tumors overexpress MDR1 [ 7 , 26].”
BackgroundEmerging Roles of SIRT1 in Cancer Drug Resistance
Wang, Z., & Chen, W. (2013) · Genes & Cancer · doi:10.1177/1947601912473826 · Cited by 82
“Traditionally, innate resistance is known to be mediated by several mechanisms including 1) reduced drug intake through mutations or loss of drug transporters, enhanced drug efflux by overexpressing ATPbinding cassette (ABC) transporters such as ABCB1 (also known as multidrug resistance protein 1 [MDR1]) and multidrug…”
BackgroundTomuleasa, C., Şoriţău, O., Rus-Ciuca, D., Pop, T., Todea, D., Moșteanu, O., Pintea, B., Foris, V., Șușman, S., Kacsó, G., et al. (2010) · PubMed · Cited by 100
Song, X., Wen, Y., Zhu, J., Zhao, F., Zhang, Z., & Li, J. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01344 · Cited by 87
Januchowski, R., Sterzyńska, K., Zawierucha, P., Ruciński, M., Świerczewska, M., Partyka, M., Bednarek-Rajewska, K., Brązert, M., Nowicki, M. O., Zabel, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18278 · Cited by 102
“These transporters pump cytostatic drugs from cancer cells using energy derived from ATP hydrolysis [4].”
BackgroundEpithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression
Jiang, Z., Sun, Y., Wang, S., & Ruan, J. (2017) · Journal of Cancer · doi:10.7150/jca.19079 · Cited by 94
“ABC transporters often overexpressed in the majority of drug-resistant tumors [1, 2], and act as protectors of tumor cells by changing drug concentrations in both intracellular and extracellular environments.”
BackgroundDing, M., Zeng, X., He, X., Li, J., Tan, H. S., & Fu, Q. (2014) · Biomacromolecules · doi:10.1021/bm500506v · Cited by 87
Multifunctional Electrospun Nanofibers for Enhancing Localized Cancer Treatment
Fu, Y., Li, X., Ren, Z., Mao, C., & Han, G. (2018) · Small · doi:10.1002/smll.201801183 · Cited by 84
Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells
Christena, L. R., Subramaniapillai, S. G., Ulaganathan, V., & Nagarajan, S. (2019) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2019.1607248 · Cited by 93
“Limiting intracellular accumulation of anti-cancer drugs would lead to reduction in: apoptosis, activation of DNA repair, altered cell cycle check points, drug detoxification that ultimately results in decreased cytotoxicity of these drugs (Gottesman et al. 2002).”
BackgroundMirrahimi, M., Beik, J., Mirrahimi, M., Alamzadeh, Z., Teymouri, S., Mahabadi, V. P., Eslahi, N., Tazehmahalleh, F. E., Ghaznavi, H., Shakeri‐Zadeh, A., et al. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.272 · Cited by 87
Palanikumar, L., Kalmouni, M., Houhou, T., Abdullah, O., Ali, L., Pasricha, R., Straubinger, R., Thomas, S. A., Afzal, A. J., Barrera, F. N., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04564 · Cited by 91
Dissecting Variability in Responses to Cancer Chemotherapy Through Systems Pharmacology
Yang, R., Niepel, M., Mitchison, T. K., & Sorger, P. K. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.96 · Cited by 85
Bhatia, A. K., Schäfer, H., & Hrycyna, C. A. (2005) · Biochemistry · doi:10.1021/bi0503807 · Cited by 86
“ABCG2 is considered a half-transporter and is thought to form a dimer or higher order oligomer (4-6) because numerous other ABC transporters are roughly twice the molecular weight and have two NBDs and two or more TMDs (7-9).”
BackgroundInfluentialInfluence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism
Joyce, H., McCann, A., CLYNES, M. M., & Larkin, A. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1028356 · Cited by 89
“Selected anticancer drug substrates of ATP-binding cassette efflux transporters [153-161].”
BackgroundMapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells
Heimerl, S., Bosserhoff, A., Langmann, T., Ecker, J., & Schmitz, G. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282a7e0b9 · Cited by 100
Prasad, P., Shuhendler, A. J., Cai, P., Rauth, A. M., & Wu, X. Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.008 · Cited by 94
“These transporters increase the ability of cancer cells to actively transport anti-cancer agents, such as Dox, out of the cells against concentration gradients, causing a reduction in drug cytotoxicity [12–16].”
BackgroundAntiprotease therapy in cancer: hot or not?
Lah, T. T., Alonso, M. B. D., & Noorden, C. J. F. V. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.257 · Cited by 100
“A good example of gain of function is the acquisition by cancer cells of resistance to chemotherapy, due in part to the induction of multi-drug resistance pump proteins in these cells [5].”
BackgroundCheng, Q., Du, L., Meng, L., Han, S., Wei, T., Wang, X., Wu, Y., Song, X., Zhou, J., Zheng, S., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11789 · Cited by 85
Yang, G., Lv, R., He, F., Qu, F., Gai, S., Du, S., Wei, Z., & Yang, P. (2015) · Nanoscale · doi:10.1039/c5nr03085d · Cited by 85
Zhao, S., Tan, S., Guo, Y., Huang, J., Chu, M., Liu, H., & Zhang, Z. (2013) · Biomacromolecules · doi:10.1021/bm4005113 · Cited by 85
Recent insights into synthetic β -carbolines with anti-cancer activities
Kumar, S., Singh, A., Kumar, K., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.059 · Cited by 86
Zhitomirsky, B., Farber, H., & Assaraf, Y. G. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13485 · Cited by 85
“ABC transporters play an important physiological role in protecting cells from numerous endogenous and exogenous toxic compounds and as such have been found to contribute to cancer multidrug resistance (MDR) by preventing various chemotherapeutic agents from entering cancer cells and exerting their cytotoxic activity…”
BackgroundBai, L., Wang, A., Zhang, Y., Xu, X., & Zhang, X. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.03.014 · Cited by 87
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
Pang, X., Liu, X., Liu, Y., Liu, W., Li, Y.-R., Yu, G.-X., Tian, X., Zhang, Y., Song, J., Jin, C., et al. (2021) · Molecules · doi:10.3390/molecules26144250 · Cited by 85
Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism
Yu, Q., Ni, D., Kowal, J., Manolaridis, I., Jackson, S. M., Stahlberg, H., & Locher, K. P. (2021) · Nature Communications · doi:10.1038/s41467-021-24651-2 · Cited by 80
Shen, H., Xu, W., Luo, W., Zhou, L., Wei, Y. Q., Chen, F., Wu, C., Chen, Q., & Han, X. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.01.013 · Cited by 85
“Binding of Sp1 to the GC element and interaction of the trimeric transcription factor NF-Y and YB-1 with the CCAAT box activates the mdr1 promoter in several cell lines [22–24].”
BackgroundLazarova, N., Zoghbi, S. S., Hong, J. S., Seneca, N. M., Tuan, E., Gladding, R. L., Liow, J., Taku, A., Innis, R. B., & Pike, V. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800510m · Cited by 89
Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers
Aliabadi, H. M., Landry, B. K., Remant, K. C., Neamnark, A., Suwantong, O., & Uludağ, H. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201000402 · Cited by 87
Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance
Hembruff, S. L., Laberge, M. L., Villeneuve, D. J., Guo, B., Veitch, Z. W. N., Cecchetto, M., & Parissenti, A. M. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-318 · Cited by 85
“A wide variety of proteins or protein mutations have been found to play a role in drug resistance in vitro, but their relevance clinically remains to be established [2-4].”
BackgroundAnnereau, J., Szakács, G., Tucker, C. J., Arciello, A., CARDARELLI, C. O., Collins, J., Grissom, S. F., Zeebèrg, B. R., Reinhold, W. C., Weinstein, J. N., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.005009 · Cited by 91
“Mechanisms leading to multidrug resistance (MDR) include increased drug efflux (Shen et al., 1986b; Gottesman et al., 2002), decreased drug uptake (Shen et al., 2000), recruitment of drug-processing and metabolizing enzymes (Schuetz et al., 1996), the activity of conjugating enzymes (Goto et al.,…”
BackgroundSelf-citationFluoxetine and reversal of multidrug resistance
Peer, D., & Margalit, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.06.003 · Cited by 85
“An entirely different situation exists in MDR tumor cells, due to over expression of extrusion transporters from the ABC superfamily [1–5,8–10].”
BackgroundInfluentialModulation of p‐glycoprotein function by caveolin‐1 phosphorylation
Barakat, S., Demeule, M., Pilorget, A., Régina, A., Gingras, D., Baggetto, L. G., & Béliveau, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04410.x · Cited by 85
Convergent Evolution, Evolving Evolvability, and the Origins of Lethal Cancer
Pienta, K. J., Hammarlund, E. U., Axelrod, R., Amend, S. R., & Brown, J. S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1158 · Cited by 96
“Metastatic disease remains incurable because, somehow, tumors evolve resistance to all known natural and synthetic compounds, including anti-cancer therapies (4-13).”
BackgroundKweon, S. H., Song, J. H., & Kim, T. S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.147 · Cited by 92
Chandra, P., Noh, H., Pallela, R., & Shim, Y. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.03.069 · Cited by 84
“It includes two nucleotide-binding and two membrane-spanning domains, acts as energy dependent pump that decreases intracellular drug concentrations lower than the effective therapeutic levels (Bellamy, 1996; Gottesman et al., 2002).”
BackgroundMechanisms of cancer: multidrug resistance
Filipits, M. (2004) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2004.10.001 · Cited by 91
Saeki, T., Nomizu, T., Toi, M., Ito, Y., Noguchi, S., Kobayashi, T., Asaga, T., Minami, H., Yamamoto, N., Aogi, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1646 · Cited by 92
Zhang, Z.-T., Huang-Fu, M.-Y., Xu, W.-H., & Han, M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.02.009 · Cited by 82
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.